𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dose–response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder

✍ Scribed by Per Bech; Daniel K. Kajdasz; Vibeke Porsdal

Publisher
Springer
Year
2006
Tongue
English
Weight
166 KB
Volume
188
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Duloxetine in the treatment of binge eat
Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial
✍ Guerdjikova, Anna I. ;McElroy, Susan L. ;Winstanley, Erin L. ;Nelson, Eric B. ;M 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 879 KB

## Abstract ## Objective: This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. ## Method: In this 12‐week, double‐blind, placebo‐controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders‐IV‐TR B

Safety and tolerability of duloxetine in
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials
✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random

A double-blind, multicenter trial compar
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
✍ Lesley M. Arnold; Yili Lu; Leslie J. Crofford; Madelaine Wohlreich; Michael J. D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder. ## Methods This study was a randomized, double‐blind, placebo‐controlled trial co

Assessment of depressive symptoms and fu
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol
✍ Tina Marie Myers Oakes; Adam L. Myers; Lauren B. Marangell; Jonna Ahl; Apurva Pr 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 3 views

Objective Return of functional ability is a central goal in the treatment of major depressive disorder. We conducted two trials with the same protocol that was designed to assess functioning after 8 Weeks of treatment with duloxetine. Methods The a priori primary outcome was improvement in the Hamil